SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	LL-37	KPV	BPC-157
Research Topic	Tissue / Repair Research	Tissue / Repair Research	Tissue / Repair Research
Pharmacology	Cathelicidin host-defence peptide	Experimental melanocortin-derived tripeptide / anti-inflammatory research	Experimental synthetic pentadecapeptide / mechanism not established
PrimeCore Class	Class BInvestigational	Class CExperimental / limited evidence	Class CExperimental / limited evidence
Evidence Grade	Grade CEarly human evidence	Grade EPreclinical evidence	Grade DLimited / observational evidence
Evidence boundary	LL-37 has investigational topical wound data, not blanket antimicrobial approval. The 148-patient phase IIb trial did not improve healing significantly in the overall cohort; post-hoc large-ulcer signals require confirmation. FDA describes impurity/immunogenicity concerns and nonclinical safety signals. Topical findings do not establish injection safety.	A melanocortin-derived tripeptide with predominantly preclinical evidence and no established human therapeutic efficacy.	An experimental peptide supported mainly by preclinical research; animal tissue-repair findings do not establish human treatment efficacy.
Unknowns	Insufficient data in the current dataset	human pharmacokinetics, pharmacodynamics, efficacy and safety for every route molecular target and the role of PepT1 or melanocortin receptors in clinical settings whether effects in mouse colitis models translate to ulcerative colitis or Crohn's disease identity, purity, aggregation and sterility of products marketed under the KPV name long-term immunogenicity, reproductive and carcinogenic risks final PCAC vote documentation and FDA decision following the July 2026 meeting	English translation is not yet verified for 6 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) ประสิทธิผลจริงสำหรับ tendon, ligament, muscle, bone, joint หรือ gastrointestinal conditions ความปลอดภัยระยะยาว rare adverse events และผลในผู้มีโรคประจำตัว human pharmacokinetics ที่น่าเชื่อถือสำหรับเส้นทางต่าง ๆ molecular target และความหมายทางคลินิกของ angiogenesis/NO effects ผลลัพธ์ของ Phase 2 NCT07437547 ซึ่งยังไม่ประกาศผล ผลโหวตและข้อสรุปสุดท้ายจาก FDA PCAC เดือนกรกฎาคม 2026 ซึ่ง minutes ยังไม่เผยแพร่บนหน้าที่ตรวจ
Limitations	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) Host-defence peptide ≠ approved antibiotic; ไม่ยืนยันการรักษาการติดเชื้อทุกชนิดหรือ systemic immune boosting	There are no verified human exposure studies. Human cell cultures and excised human skin are laboratory models, while disease findings come mainly from mice. Formulation studies confound KPV with nanoparticles, hydrogels or barrier-disrupting delivery. FDA also found major identity and quality-characterization gaps for free base and acetate. Therefore clinical benefit, route-specific safety and product equivalence remain unestablished.	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) human evidence มีขนาดเล็กมาก ไม่มีกลุ่มควบคุมในงานที่ตีพิมพ์หลัก ใช้ self-reported outcomes หรือ safety markers ระยะสั้น และมาจากคลินิกเดียวกันบางส่วน งาน UC มีรายละเอียดจำกัด งานส่วนใหญ่เป็นสัตว์/เซลล์ และความไม่ชัดของ free base เทียบ acetate ทำให้เทียบข้อมูลข้ามผลิตภัณฑ์ไม่ได้ การลงทะเบียน trial ไม่ใช่ผลการทดลอง
Sources	FDA · Cathelicidin LL-37 safety-risk entry HEAL LL-37 · PMID 34687253 First-in-human wound trial · PMID 25041740	https://www.fda.gov/media/193346/download https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://pubmed.ncbi.nlm.nih.gov/18092346/ https://pubmed.ncbi.nlm.nih.gov/18061177/ https://pubmed.ncbi.nlm.nih.gov/28343991/ https://pubmed.ncbi.nlm.nih.gov/15102092/ https://pubmed.ncbi.nlm.nih.gov/27458604/ https://pubmed.ncbi.nlm.nih.gov/28143741/ https://products.mhra.gov.uk/	https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193343/download https://www.fda.gov/media/193711/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://pubmed.ncbi.nlm.nih.gov/34324435/ https://pubmed.ncbi.nlm.nih.gov/40131143/ https://pubmed.ncbi.nlm.nih.gov/40756949/ https://clinicaltrials.gov/study/NCT07437547 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://products.mhra.gov.uk/
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.